Rule 8.1- C.A.T.
June 21 2006 - 1:11PM
UK Regulatory
RNS Number:9809E
Goldman Sachs & Co.
21 June 2006
FORM 8.1
LATE DISCLOSURE
DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
(Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers)
1. KEY INFORMATION
Name of person dealing (Note 1) Goldman Sachs & Co.
Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
Class of relevant security to which the Ordinary shares
dealings being disclosed relate (Note 2)
Date of dealing 30 May 2006
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
Number Number
(%) (%)
(1) Relevant securities 0 0
(0.00%) (0.00%)
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 0 0
(0.00%) (0.00%)
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
Number Number
(%) (%)
(1) Relevant securities
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
(c) Rights to subscribe (Note 3)
Class of relevant security: Details
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of securities Price per unit (Note 5)
Sale * 200 24.48 USD
*Goldman Sachs brought this trade to the attention of the Panel and the
consequences of this transaction are being considered.
(b) Derivatives transactions (other than options)
Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)
e.g. CFD
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. Expiry Option money
purchasing, to which the option American,
e.g. call option varying etc. relates (Note 7) price European etc. date paid/received per
unit (Note 5)
(ii) Exercising
Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
(d) Other dealings (including new securities) (Note 4)
Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9)
NO
Date of disclosure 21 June 2006
Contact name Peter Highton
Telephone number +44-207-774-1935
Name of offeree/offeror with which associated Astrazeneca
Specify category and nature of associate status (Note 10) Adviser
Notes
The Notes on Form 8.1 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCDFLFLQQBBBBK
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024
